Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025
Published: December 5, 2025 Protara Therapeutics, Inc. (NASDAQ: TARA) is ending the week in dramatic fashion. After a string of positive clinical updates for its lead cell therapy TARA‑002, the company has tapped equity markets with a $75 million public